Literature DB >> 2981328

Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

B Vroman, J Luka, M Rodriguez, G R Pearson.   

Abstract

A monoclonal antibody designated V3 was produced against a late protein associated with the Epstein-Barr virus-induced viral capsid antigen complex. The antibody reacted with discrete patches in the nuclei of infected cells as well as with virus particles, as shown by immunofluorescence and ultrastructural immunoperoxidase staining. The molecular weight of the protein precipitated by this monoclonal antibody was ca. 160,000. All anti-viral capsid antigen antibody-positive sera tested in an enzyme-linked immunosorbent assay reacted with this purified protein. The synthesis of the antigen was inhibited by phosphonoacetic acid but was not affected by tunicamycin, indicating that this was a late nonglycosylated viral protein. No differences were noted between the protein isolated from the P3HR-1 and B-95-8 cell lines as determined by immunoprecipitation and peptide mapping. By isoelectric focusing, this protein had a pI on the basic side ranging from 7.5 to 9.0.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981328      PMCID: PMC254985     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Two distinct antigenic components in an Epstein-Barr virus-related early product induced by halogenated pyrimidines in non-producing human lymphoblastoid cells.

Authors:  K Sugawara; T Osato
Journal:  Nat New Biol       Date:  1973-06-13

2.  Production of antigens associated with Epstein-Barr virus in experimentally infected lymphoblastoid cell lines.

Authors:  G R Pearson; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1971-06       Impact factor: 13.506

3.  Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen.

Authors:  B C Strnad; T Schuster; R Klein; R F Hopkins; T Witmer; R H Neubauer; H Rabin
Journal:  J Virol       Date:  1982-01       Impact factor: 5.103

4.  Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen.

Authors:  M Kishishita; J Luka; B Vroman; J F Poduslo; G R Pearson
Journal:  Virology       Date:  1984-03       Impact factor: 3.616

5.  Partial purification of the Epstein-Barr virus nuclear antigen(s).

Authors:  T B Sculley; T Kreofsky; G R Pearson; T C Spelsberg
Journal:  J Biol Chem       Date:  1983-03-25       Impact factor: 5.157

6.  Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies.

Authors:  G R Pearson; B Vroman; B Chase; T Sculley; M Hummel; E Kieff
Journal:  J Virol       Date:  1983-07       Impact factor: 5.103

7.  Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form.

Authors:  A J Morgan; J R North; M A Epstein
Journal:  J Gen Virol       Date:  1983-02       Impact factor: 3.891

8.  Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein.

Authors:  L F Qualtiere; R Chase; G R Pearson
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

9.  A sensitive enzyme-linked immunosorbent assay (ELISA) against the major EBV-associated antigens. I. Correlation between ELISA and immunofluorescence titers using purified antigens.

Authors:  J Luka; R C Chase; G R Pearson
Journal:  J Immunol Methods       Date:  1984-02-24       Impact factor: 2.303

10.  Monoclonal antibody specific for capsid antigen of Epstein-Barr virus.

Authors:  K Takada; S Fujiwara; S Yano; T Osato
Journal:  Med Microbiol Immunol       Date:  1983       Impact factor: 3.402

View more
  13 in total

1.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein.

Authors:  J Luka; G Miller; H Jörnvall; G R Pearson
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

4.  Gene mapping and expression of two immunodominant Epstein-Barr virus capsid proteins.

Authors:  W M van Grunsven; E C van Heerde; H J de Haard; W J Spaan; J M Middeldorp
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

5.  Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen.

Authors:  R Fox; R Sportsman; G Rhodes; J Luka; G Pearson; J Vaughan
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

6.  Two 21-kilodalton components of the Epstein-Barr virus capsid antigen complex and their relationship to ZEBRA-associated protein p21 (ZAP21).

Authors:  T R Serio; A Angeloni; J L Kolman; L Gradoville; R Sun; D A Katz; W Van Grunsven; J Middeldorp; G Miller
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

7.  Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins.

Authors:  L S Young; S Finerty; L Brooks; F Scullion; A B Rickinson; A J Morgan
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms.

Authors:  Stuart Prince; Sinead Keating; Ceri Fielding; Paul Brennan; Eike Floettmann; Martin Rowe
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Detection of Eber-1 RNA in primary brain lymphomas in immunocompetent and immunocompromised patients.

Authors:  R Bashir; B McManus; C Cunningham; D Weisenburger; F Hochberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.

Authors:  Luke R Williams; Laura L Quinn; Martin Rowe; Jianmin Zuo
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.